<DOC>
	<DOCNO>NCT00787059</DOCNO>
	<brief_summary>This research study design determine : 1 ) whether gene transfer use agent call Ad5.hAC6 ( adenovirus-5 encode human adenylyl cyclase type 6 ) give safely patient congestive heart failure ( CHF ) 2 ) whether agent may benefit heart failure . Gene transfer process gene introduce cell cell produce specific protein gene directs , case , protein know adenylyl cyclase type 6 ( AC6 ) . The gene carry heart cell modify virus . The virus modify adenovirus ( Ad5 ) , virus sometimes cause brief cold . In extensive animal experiment , find increased amount AC6 protein heart cell appear make heart pump vigorously .</brief_summary>
	<brief_title>AC6 Gene Transfer CHF</brief_title>
	<detailed_description>This research study design determine : 1 ) whether gene transfer use agent call Ad5.hAC6 ( adenovirus-5 encode human adenylyl cyclase type 6 ) give safely patient congestive heart failure ( CHF ) 2 ) whether agent may benefit heart failure . Gene transfer process gene introduce cell cell produce specific protein gene directs , case , protein know adenylyl cyclase type 6 ( AC6 ) . The gene carry heart cell modify virus . The virus modify adenovirus ( Ad5 ) , virus sometimes cause brief cold . In extensive animal experiment , find increased amount AC6 protein heart cell appear make heart pump vigorously .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion Criteria 1 . Male nonpregnant female patient age 1880 year age 2 . ≥3month history heart failure 3 . Compensated ( stable ) CHF intravenous inotropes , vasodilator diuretic , optimal medical device therapy define AHA/ACC Guidelines 4 . LV ejection fraction ( optimal therapy ) great 40 % 5 . Implanted cardiac defibrillator 6 . At least one major coronary artery ( graft ) &lt; 50 % proximal obstruction 7 . Patients unable walk ( spinal injury , orthopedic problem ) enrol criterion meet . 8 . Women childbearing capacity must negative pregnancy test within 2 day test substance administration , female male patient must willing use birth control sex 12w test substance administration female partner childbearing capacity . 9 . Subjects willingly provide informed consent consistent ICHGCP guideline Exclusion Criteria 1 . Unstable Class IV angina 2 . Coronary revascularization plan predict next 6 month 3 . Ischemic myocardium 3 region single perfusion bed , assess stress echocardiography jeopardize viable myocardium &gt; 15 % perfusion imaging . 4 . ≥50 % occlusion `` unprotected '' leave main coronary artery . If arterial venous conduit provide blood flow distal leave coronary circulation ( ie , patent bypass graft ) leave main disease `` protected '' patient exclude . The cardiologist perform cardiac catheterization make decision . 5 . 2° AV Block ( Mobitz 2 ) 3° AV block unless pacemaker present 6 . Hospitalization CHF require intravenous inotropes vasodilator past 4 week 7 . History biopsy proven myocarditis 8 . Myocardial infarction previous 6 month 9 . Restrictive , hypertrophic infiltrative cardiomyopathy chronic pericarditis 10 . Previous plan organ transplant recipient donor . 11 . Thrombocytopenia ( &lt; 100,000 platelets/µl ) bleed diathesis 12 . COPD require supplemental oxygen home 13 . AST &gt; 2 time upper limit normal chronic liver disease cirrhosis Hepatitis C Virus ( HCV ) . Patients HCV eligible two condition meet : ) liver function test normal ; AND b ) liver biopsy normal show mild fibrosis . 14 . Current predict hemodialysis within 12 month estimate glomerular filtration rate ( EGFR ) &lt; 30 ml/min . On online EGFR calculator use sex , age , body weight serum creatinine available : www.kidney.org/professionals/kdoqi/gfr_calculator.cfm . Use high two EGFR result , base upon MDRD CKDEPI formula . 15 . CVA TIA &lt; 6 month prior enrollment 16 . Patients immunosuppressed medicine ( corticosteroid , methotrexate , cyclophosphamide , cyclosporine ) , illnesses ( AIDS , HIV ) , neutrophil count &lt; 1000/mm3 17 . Patients receive investigational drug therapy within 30 day enrollment include gene transfer 18 . Patients diseases CHF , opinion investigator , put subject risk adversely affect result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Adenylyl Cyclase</keyword>
	<keyword>AC6</keyword>
	<keyword>adenovirus</keyword>
	<keyword>gene therapy</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>intracoronary</keyword>
	<keyword>nitroprusside</keyword>
</DOC>